A Two-Arm, Open-label, Randomized Phase II Study of Pembrolizumab (MK-3475) Monotherapy versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)

ID Number 16-1526

Principal Investigator(s)
Krzysztof J Misiukiewicz

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to test the safety, tolerability, and anti-tumor activity of an experimental drug called, pembrolizumab verses standard of care chemotherapies in subjects with recurrent and/or metastatic nasopharyngeal cancer.  An experimental drug is not approved by the Unites States FDA for use except in research studies.

Contact Information
Jill Ransbottom
(212) 824-7309

Recruiting Patients: Yes